Professor Marco Ruella of the US presents at Nature Webinar using Curiox AUTO1000
"Expected essential item application in future cell therapy development and manufacturing processes"
Curiox Biosystems is showing strong performance. News that research results using cell analysis process automation systems were introduced at a globally renowned bio conference appears to be influencing the stock price.
At 9:49 AM on the 23rd, Curiox Biosystems was trading at 37,000 KRW, up 12.63% from the previous day.
Curiox Biosystems, a global leader in cell analysis process automation, officially announced on the 23rd that Professor Marco Ruella from the United States presented CAR-T research results using the AUTO1000 device equipped with Lamina Wash technology through a webinar hosted by the world-renowned academic journal Nature.
Professor Marco Ruella of the University of Pennsylvania School of Medicine was affiliated with Dr. Carl June’s lab, which succeeded in commercializing CAR-T therapy and developed Kymriah, and is a top global authority in this field boasting overwhelming research experience in innovative cell therapy development.
A Curiox representative said, "About 500 world-class medical experts and researchers participated in the webinar hosted by Nature on the 15th," adding, "There was high interest in the research presentation on the potential for developing new CAR-T therapies using next-generation technology presented by Professor Marco Ruella."
Professor Marco Ruella’s research topic was ‘Resistance to CAR-T Cell Immunotherapy for Hematologic Malignancies,’ presenting studies on tumor evasion mechanisms and other limitations to overcome the boundaries of CAR-T therapy.
Using next-generation technologies such as scRNA sequencing and spatial transcriptomics, the focus was on characterizing resistance mechanisms and developing new therapeutics. The process by which CAR-T cells recognize and destroy tumor cells was explained through videos, emphasizing how the therapy shows long-term effectiveness. He shared data demonstrating the long-term effects of several FDA-approved CAR-T therapies, showing therapeutic effects in aggressive lymphomas.
Curiox CEO Namyong Kim stated, "It is highly significant that a leading authority in the field of cell immunotherapy presented CAR-T research results using the AUTO1000 device equipped with Lamina Wash technology." He added, "We will do our best to ensure that Curiox products become essential items that accelerate the development of existing cell therapies and produce positive outcomes in practical clinical applications in the future development and manufacturing processes of cell therapies."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
